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Abstract: Noninvasive mechanical ventilation (NIMV) is effective in the treatment of patients 
with acute respiratory failure (ARF). It proved to reduce the need of endotracheal intubation 
(ETI), the incidence of ETI-associated pneumonia, and mortality compared to nonventilated 
patients. A particular aspect concerns the outcome of NIMV in patients referring to an emergency 
room (ER) for ARF, and with a do-not-intubate (DNI) status due to advanced age or critical 
conditions. The aim of our study is to assess the outcome of NIMV in a group of elderly patients 
with acute hypercapnic ARF who had a DNI status. An overall number of 62 subjects (30 males, 
32 females, mean age 81 ± 4.8 years, range 79–91 years) referred to our semi-intensive respiratory 
department were enrolled in the study. The underlying diseases were severe chronic obstructive 
pulmonary disease (COPD) in 50/62 subjects, restrictive thoracic disorders in 7/62 subjects, and 
multiorgan failure in 5/62 subjects. Fifty-four/62 patients were successfully treated with NIMV 
while 2/62 did not respond to NIMV and were therefore submitted to ETI (one survived). Among 
NIMV-treated patients, death occurred in 6 patients after a mean of 9.9 days; the overall rate 
of NIMV failure was 12.9%. Negative prognostic factors for NIMV response proved to be: an 
older age, a low Glasgow Coma Score, a high APACHE score at admission, a high PaCO2 after 
12 hours and a low pH both after 1 and 12 hours of NIMV. We conclude that elderly patients 
with acute hypercapnic ARF with a DNI status can be successfully treated by NIMV.
Keywords: acute respiratory failure, noninvasive mechanical ventilation, endotracheal 
intubation, do-not-intubate, COPD, oxygen therapy
Introduction
Noninvasive mechanical ventilation (NIMV) is effective in the treatment of patients 
with acute respiratory failure (ARF), as shown by controlled trials and meta-analysis 
(Bott et al 1993; Kramer et al 1995; Plant et al 2000; Brochard et al 2002; Lightowler 
et al 2003). In particular, NIMV proved to reduce the need of endotracheal intubation 
(ETI) (Antonelli et al 1998), to prevent ETI-associated pneumonia (Nourdine 
et al 1999; Carlucci et al 2001) and to decrease incidence of mortality compared 
to nonventilated patients (Keenan et al 2004). During last decades NIMV use is 
continuously increasing (Carlucci et al 2001; Demoule et al 2006), despite consensus 
documents established the rationale, and therefore also some limitations, to resort to 
NIMV in severe chronic obstructive lung disease (COPD), restrictive thoracic disorders, 
and nocturnal hypoventilation (ACCP 1999). Nevertheless, NIMV may have some 
negative effects, for example the delay in using ETI when the respiratory conditions 
require such measure, an unsatisfactory outcome in patients with ARF due to severe 
community acquired pneumonia, and the risk to develop an aspiration pneumonia in 
patients with altered level of consciousness (Jolliet et al 2001; Metha and Hill 2001; 
Esteban et al 2004).International Journal of COPD 2008:3(4) 798
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A particular aspect is the outcome of NIMV in patients 
referring to an emergency department for ARF, who have a 
do-not-intubate (DNI) status because of elderly age or critical 
clinical conditions.
The aim of our study was the evaluation of the outcome 
of NIMV in a group of DNI elderly patients with hypercapnic 
ARF mainly due to COPD exacerbations.
Materials and methods
Patients
Sixty-two patients, 30 males and 32 females, mean 
age 81 ± 4.8 years, range 79–91 years, with hypercapnic 
ARF (deﬁ  ned by PaCO2   45 mm Hg and pH   7.35) 
(Weiss and Hudson 1994), hospitalized in the semi-intensive 
respiratory medicine unit of Vimercate Hospital, Milan, 
Italy were enrolled in the study. The inclusion criteria 
were age  75 years and a DNI status, as established by 
the intensive care physician, on the basis of advanced age 
and unfavorable clinical status. In Italy, exhaustive laws 
regulating the matter are currently lacking (Zamparetti et al 
2006). In 50 patients the underlying disease was severe 
COPD (stage 4 GOLD) in 50/62 patients, restrictive thoracic 
disorders (mainly severe kyphoscoliosis) in 7/62, and 
multiorgan failure in 5/62. All patients were already treated 
with long-term oxygen therapy (LTOT).
Methods
Severity-of-illness classiﬁ  cation was assessed by the Acute 
Physiology and Chronic Health Evaluation (APACHE) II 
(Knaus et al 1985) and level of consciousness by the Glasgow 
Coma Score (GCS) (Teasdale and Jennet 1974). Also PaO2/
FiO2 ratio, PaCO2, pH, respiratory rate, heart rate, and blood 
pressure were measured. The main characteristics of subjects 
at baseline are reported in Table 1.
All patients were under treatment with antibiotics, systemic 
corticosteroids, and bronchodilators. Those with multiorgan 
failure received the appropriate medical therapy.
NIMV was started in all patients already in the ER by the 
pneumologist on duty, and was continued in the semi-intensive 
respiratory medicine unit. NIMV was performed in 59 patients 
by pressure support, bilevel mode, and in 3 patients by 
volume support mode. Assisted controlled ventilation, set-
ting a lower than spontaneous respiratory rate was used in 
conscious patients, while in the others, a controlled ventilation 
was used. Ventilators models Helia and Elisee 150 from 
Vivisol (Savigny Le Temple, France), with oronasal masks 
as interface, were used. Inspiratory (IPAP) and expiratory 
positive airway pressure (EPAP) were set according to 
patient’s tolerance and blood gas parameters. All blood 
gas parameters were measured after one and 12 hours of 
continuous ventilation and at discharge.
The local Ethical Committee approved the procedures 
of the study, and patients or their relatives (depending on 
patient’s clinical conditions) gave their verbal informed 
consent to NIMV.
Statistical analysis
The results were expressed as mean ± SD. Mean values 
of considered parameters in patients successfully or 
unsuccessfully treated by NIMV were compared, for both 
intergroup and intragroup analysis, using ANOVA test. 
The one-way ANOVA was used to examine difference 
between groups at the enrolment and ANOVA with post-hoc 
analysis was used for repeated measures to test the trend of 
parameters for each group of patients, considering signiﬁ  cant 
a p value   0.05. The small number of patients unsuccessfully 
treated prevented the comparison of categorical variables or 
the analysis of odds ratio by multivariate logistic regression.
Results
Fifty-four/62 patients were successfully treated with NIMV, 
and discharged after a mean duration of hospitalization 
of 13.7 ± 5.1 days. In two patients signiﬁ  cant changes in 
PaCO2 and pH values did not occur and, following the 
consent by their relatives, they were submitted to ETI, and 
one survived. In other six patients the treatment was unable to 
prevent death, which occurred after a mean of 9.9 ± 8.3 days 
of hospitalization. One subject, a 88-year-old male, died 
before the 12 hours assessment: he had an exacerbation in 
severe COPD, with a GCS score of 6, an APACHE score 
of 37, a PaO2/FiO2 ratio of 145, a PaCO2 of 96 mm Hg, and 
Table 1 Characteristics of patients at admittance
Parameter Mean value (SD)
GCS 11.1 ± 3.5
APACHE 2 score 27.2 ± 5.8
PaO2 49.0 ± 16.5
PaCO2 85.6 ± 18.0
pH 7.23 ± 0.09
HCO3 35.6 ± 6.5
FiO2 0.28 ± 0.1
Respiratory rate 31.9 ± 8.6
Heart rate 99.3 ± 22.2
Systolic blood pressure 98.8 ± 21.5
Abbreviations: GCS, glasgow coma score; SD, standard deviation.International Journal of COPD 2008:3(4) 799
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a pH of 6.9; after one hour of NIMV in bilevel mode, with 
IPAP 25 cm H2O and EPAP 7 cm H2O, the ratio PaO2/FiO2 
moved to 103, the PaCO2 to 88 mm Hg, and the pH to 7.01. 
In the other six cases, death occurred for pneumonia (2/6), 
multiorgan failure (2/6), or ARF (2/6). The NIMV failure in 
the studied patients was 12.9%.
Table 2 reports the mean age, GCS and APACHE scores, 
and blood gas parameters at admission, and after both 1 and 
12 hours in patients successfully or unsuccessfully treated. 
NIMV-nonresponders had a lower GCS and an higher 
APACHE score at baseline compared to NIMV-responders, 
while no differences in PaO2/FiO2, PaCO2 or pH were observed. 
NIMV-nonresponders had a signiﬁ  cantly higher mean value of 
PaCO2 after 12 hours and a signiﬁ  cantly lower pH value both 
after 1 and 12 hours. Intra-group comparison by ANOVA test 
with post-hoc analysis showed no signiﬁ  cant change in PaO2/
FiO2 and signiﬁ  cant improvement in PaCO2 and pH (p   0.0001) 
in successfully treated, while no signiﬁ  cant change for any 
parameter was found in unsuccessfully treated patients.
Thirty-five/54 patients who recovered after NIMV 
continued ventilation at home to control hypercapnia 
(PaCO2 = 52.5 mm Hg), while 19/54 needed only oxygen 
therapy (PaCO2 = 45.4 mm Hg) (p = 0.001).
Discussion
The effectiveness of NIMV in ARF patients was clearly 
demonstrated by numerous randomized trials (Bott et al 1993; 
Kramer et al 1995; Wisocki et al 1995; Antonelli et al 2000; 
Plant et al 2000; Brochard et al 2002; Ferrer et al 2003). 
Studies regarding respiratory failure resulting from COPD 
exacerbations were included in a meta-analysis, that conﬁ  rmed 
the favorable outcome of NIMV in such population (Lightowler 
et al 2003). However, the optimal settings and performances 
deriving from randomized trials could not be applicable in 
routine practice of NIMV, and therefore data deriving from 
observational studies are also important. A recent prospective 
observational study conducted in France on 524 patients 
reported a significantly better outcome in subjects with 
acute-on-chronic respiratory failure compared to those with 
acute de novo respiratory failure, showing a mortality rate of 
20% and 41%, respectively (Demoule et al 2006).
Age is an important issue to be considered; the increasing 
duration of life in the general population and the increasing 
life expectancy in COPD patients due to LTOT make 
common to ﬁ  nd elder patients with severe ARF in ER. 
In these patients, the balance for ETI—as assessed by the 
ER physician—is often critical, leaving NIMV as the only 
treatment option.
The present study, that included elderly patients (mean 
age of 81 years) with acute-on-chronic respiratory failure 
(all patients were on LTOT), shows a low mortality rate 
(about 13%), that is particularly favourable in this setting. In 
fact previous studies reported the older age as a predictor of   
NIMV failure in patients with ARF (Antonelli et al 2001). 
Table 2 Difference in considered parameters in successful and unsuccessful NIMV
Successful NIMV Unsuccessful NIMV Signiﬁ  cance (p)
Mean age (years) 80.46 ± 4.61 84.75 ± 4.30 0.016
GCS 11.46 ± 3.23 8.12 ± 3.87 0.01
APACHE 2 score 26.62 ± 5.48 31.75 ± 6.14 0.018
PaO2/FiO2 178.96 ± 42.82 164.13 ± 54.47 n.s.
PaO2/FiO2 after 1 hour 155.68 ± 52.29 166.88 ± 49.32 n.s.
PaO2/FiO2 after 12 hours 174.33 ± 64.79 161.14 ± 64.54 n.s.
PaCO2 84.77 ± 14.45 92.75 ± 35.48 n.s.
PaCO2 after 1 hour 70.19 ± 12.19 81.50 ± 28.03 n.s. (0.052)
PaCO2 after 12 hours 58.10 ± 9.02 73.28 ± 26.77* 0.003
pH 7.24 ± 0.08 7.18 ± 0.16 n.s.
pH after 1 hour 7.32 ± 0.05 7.21 ± 0.15  0.001
pH after 12 hours 7.40 ± 0.06 7.33 ± 0.09* 0.01
HCO3 35.96 ± 6.31 33.64 ± 7.74 n.s.
HCO3 after 1 hour 35.37 ± 5.97 33.04 ± 8.43 n.s.
HCO3 after 12 hours 34.95 ± 4.41 34.86 ± 9.12 n.s.
Abbreviations: GCS, glasgow coma score; NIMV, noninvasive mechanical ventilation.
Note: *One patient died before 12 hours and is not considered here.International Journal of COPD 2008:3(4) 800
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Also in our study age was a critical factor, since the mean 
age of the NIMV-nonresponders was signiﬁ  cantly higher 
compared to that of the responders (87.4 years versus 
80.5 years). Regardless the age, other studies on COPD 
patients with DNI status reported a mortality rate of 
34%–43% (Levy et al 2004; Schettino et al 2005; Fernandez 
et al 2007).
In our study, the small number of subjects who failed to 
respond to NIMV—eight, with seven deaths and one patient 
undergoing ETI successfully—did not allow us to use the 
best analysis in evaluating risk factors, ie, odds ratio and 
95% conﬁ  dence interval. Some ﬁ  ndings although emerge 
with the simpler analysis used.
Firstly, the severe clinical conditions of patients, deﬁ  ned 
by a signiﬁ  cantly worse score both to GCS and APACHE 2, 
in patients who failed to respond to NIMV, conﬁ  rms previous 
observations obtained with the same parameters (Confalonieri 
et al 2005; Phua et al 2006) or using other severity-of-illness 
classiﬁ  cation, as the Simpliﬁ  ed Acute Physiology Score 
or the Logistic Organ Dysfunction (Antonelli et al 2001; 
Demoule et al 2006). In particular, a GCS lower than 11 and 
an APACHE II score higher than 29 were found to predict 
a failure risk of NIMV in patients with COPD exacerbation 
(Phua et al 2005). Moreover, a high APACHE II score proved 
to predict NIMV failure in hypercapnic ARF due both to 
COPD and non-COPD conditions (Celli and MacNee 2004). 
Such data agree with our ﬁ  ndings, obtained in COPD patients 
but also with other conditions underlying ARF.
Concerning functional parameters, baseline ratio of 
PaO2/FiO2 was not significantly different in successful 
NIMV compared with unsuccessful NIMV. Also baseline 
PaCO2 was not signiﬁ  cantly higher in unsuccessful than in 
successful NIMV, while the difference in mean value was 
close to signiﬁ  cance after 1 hour (p = 0.052) and signiﬁ  cant 
after 12 hours of NIMV (p = 0.003). Indeed, the pH value is 
the major parameter that indicates the need of ventilation in 
ARF patients (Celli and MacNee 2004) and in our population 
pH mean value was signiﬁ  cantly lower in the failure group 
than in successful one, both after 1 hour (p   0.001) and after 
12 hours of NIMV (p = 0.01). In the study by Confalonieri and 
colleagues (2005) a pH value   7.25 increased by more 
than 90% the risk of failure of NIMV. This disagrees with 
our data, since most of our successfully treated patients had 
a pH lower than 7.25. However, that study included only 
COPD exacerbations, while our patients had also different 
underlying diseases, that make the comparison not completely 
appropriate. The intra-group analysis of our patients 
showed a signiﬁ  cant improvement of pH and PaCO2 only in 
successfully treated subjects, but the overlapping between 
the two groups in physiological parameters makes difﬁ  cult to 
predict the response to NIMV in this kind of patients. Thus, 
the baseline severity of the clinical status appears to be the 
most important factor in inﬂ  uencing the outcome.
In the 54 NIMV-responders a rapid clinical improvement 
was achieved, allowing their discharge after about two weeks 
of hospitalization. Such ﬁ  ndings offer some outlook about 
the need “to evaluate the clinical outcomes of using noninva-
sive positive pressure ventilation for patients who choose to 
forego endotracheal intubation and to examine the perspec-
tives of patients, families, and clinicians on use of NPPV in 
these contexts” (Curtis et al 2007). Moreover, NIMV may 
improve the end of life care in advanced COPD, where there 
is evidence of unmet needs (Spathis and Booth 2008).
In conclusion, this study shows that elderly patients 
with ARF from COPD exacerbations (but also from 
other respiratory disorders) and with a DNI status can be 
successfully treated by NIMV.
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